Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29099494
Publication Date : //

Prognostic value of antigen expression in multiple myeloma: A PETHEMA/GEM study on 1,265 patients enrolled in four consecutive clinical trials.


Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great heterogeneity with both early and very late relapses. Amongst different MRD techniques, flow cytometry provides additional information about antigen expression on tumor cells, which could potentially contribute to stratify MRD-positive patients. We investigated the prognostic value of those antigens required to monitor MRD in 1265 newly-diagnosed patients enrolled in the GEM2000, GEM2005MENOS65, GEM2005MAS65 and GEM2010MAS65 protocols. Overall, CD19pos, CD27neg, CD38lo, CD45pos, CD81pos, CD117neg and CD138lo expression predicted inferior outcomes. Through principal-component-analysis, we found that simultaneous CD38lowCD81posCD117neg expression emerged as the most powerful combination with independent prognostic value for progression-free survival (HR:1.69; P=0.002). This unique phenotypic profile retained prognostic value among MRD-positive patients. We then used next-generation flow to determine antigen stability throughout the course of the disease, and found that the expression of antigens required to monitor MRD is mostly stable from diagnosis to MRD stages, except for CD81 whose expression progressively increased from baseline to chemoresistant tumor cells (14 vs 28%). Altogether, we showed that the phenotypic profile of tumor cells provides additional prognostic information, and could be used to further predict risk of relapse among MRD-positive patients.Leukemia accepted article preview online, 03 November 2017. doi:10.1038/leu.2017.320.

Authors : Arana P , Paiva B , Cedena M-T , Puig N , Cordon L , Vidriales M-B , Gutierrez N C , Chiodi F , Burgos L , Anglada L-L , Martinez-Lopez J , Hernandez M-T , Teruel A-I , Gironella M , Echeveste M-A , Rosiñol L , Martinez R , Oriol A , De la Rubia J , Orfao A , Blade J , Lahuerta J-J , Mateos M-V , Miguel J F S ,

Related products :

Catalog number Product name Quantity
orb61232 Carfilzomib Carfilzomib was discovered and advanced to multiple Phase 1 and 2 clinical trials, including a pivotal Phase 2 clinical trial designed to seek accelerated approval, by Proteolix, Inc. For 5 mg
27-424 Altered expression of GBX2, part of the homeobox-containing human family of DNA-binding transcription factors, is associated with therapy failure and death in patients with multiple types of cancer. 0.1 mg
EIAAB25945 Homo sapiens,Human,Myeloma-overexpressed gene protein,MYEOV,OCIM,Oncogene in multiple myeloma
orb61269 MS-275 Entinostat is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers. For research use only. 100 mg
orb61280 PF-02341066 Crizotinib is an ALK (anaplastic lymphoma kinase) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US, and undergoing clinical trials testing its safe 10 mg
orb61263 MGCD0103 Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, Hodgkin's lymphoma and acute my 10 mg
Z7020081 Multiple Tumor Tissue Array _ 15 major types tumors. Most types have duplicates from different patients with correspondi 5 slides
Z7020081 Multiple Tumor Tissue Array - 15 major types tumors. Most types have duplicates from different patients with correspondi
Z7020081 Multiple Tumor Tissue Array - 15 major types tumors. Most types have duplicates from different patients with correspondi 5 slides
Z7020081 Multiple Tumor Tissue Array _ 15 major types tumors. Most types have duplicates from different patients with correspondi 5 slides
DMMI-123-V Human Sample (Multiple Myeloma), Individual 1unit
DMMI-123-X Human Sample (Multiple Myeloma), Individual 1ml
DMMI-123-X Human Sample (Multiple Myeloma), individual 1 ml
DMMI-123-V Human Sample (Multiple Myeloma), individual 1
E0197r Mouse ELISA Kit FOR Multiple myeloma tumor-associated protein 2 homolog 96T
TRIB1_MOUSE Mouse ELISA Kit FOR Multiple myeloma tumor-associated protein 2 homolog 96T
CSB-EL003593HU Human Multiple myeloma tumor-associated protein 2(C1orf35) ELISA kit 96T
EPHA7_HUMAN Mouse ELISA Kit FOR Multiple myeloma tumor-associated protein 2 homolog 96T
EIAAB25040 Bos taurus,Bovine,MMTAG2,Multiple myeloma tumor-associated protein 2 homolog
EIAAB25041 Mmtag2,Multiple myeloma tumor-associated protein 2 homolog,Rat,Rattus norvegicus
EIAAB25042 Mmtag2,Mouse,Multiple myeloma tumor-associated protein 2 homolog,Mus musculus
MYF5 MYEOV Gene myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas)
CSB-EL003593HU Human Multiple myeloma tumor-associated protein 2(C1orf35) ELISA kit SpeciesHuman 96T
PROTSYN007 E.Coli Pilot Expression Study
MD80001 MagCustom Feasibility Study, Bead development on client demand in small scale as feasability study 1 item


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur